Global Rabies Vaccine Market Growth 2023-2029

Global Rabies Vaccine Market Growth 2023-2029

Rabies vaccine is an active immunizing agent used to prevent infection caused by the rabies virus. The vaccine works by causing your body to produce its own protection (antibodies) against the rabies virus.
LPI (LP Information)' newest research report, the “Rabies Vaccine Industry Forecast” looks at past sales and reviews total world Rabies Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Rabies Vaccine sales for 2023 through 2029. With Rabies Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Rabies Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Rabies Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Rabies Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Rabies Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Rabies Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Rabies Vaccine.
The global Rabies Vaccine market size is projected to grow from US$ 910.8 million in 2022 to US$ 1210.6 million in 2029; it is expected to grow at a CAGR of 1210.6 from 2023 to 2029.
Global Rabies Vaccine key players include Chengda, Changsheng, Prcmise, VACN, etc. Global top four manufacturers hold a share about 70%.
China is the largest market, with a share about 85%, followed by Europe, and North America, both have a share over 10 percent.
In terms of product, Vero Cell Rabies Vaccine is the largest segment, with a share over 75%. And in terms of application, the largest application is Post-exposure Prophylaxis, followed by Pre-exposure Prophylaxis.
This report presents a comprehensive overview, market shares, and growth opportunities of Rabies Vaccine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Vero Cell Rabies Vaccine
BHK
Chick Embryo Cell Rabies Vaccine
Others
Segmentation by application
Pre-exposure Prophylaxis
Post-exposure Prophylaxis
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GSK (Novartis)
Sanofi-Pasteur
Chengda
Yisheng
Prcmise
VACN
Changsheng
BCHT
Hissen
Key Questions Addressed in this Report
What is the 10-year outlook for the global Rabies Vaccine market?
What factors are driving Rabies Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Rabies Vaccine market opportunities vary by end market size?
How does Rabies Vaccine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.